Understanding cholesterol: High is bad but too low may also be risky - is low cholesterol associated with cancer?

Bratislava Medical Journal

Volumn 115, Issue 2, 2014, Pages 59-65

  Simko, V ^a   Ginter, E ^b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b INST OF PREV AND CLINICAL MEDICINE   (Slovakia)

Author keywords

Cancer; Cardiovascular disease (CVD); High density lipoprotein cholesterol (HDL C); Hydroxy methylglutaryl coenzyme a reductase (HMGCR); Lipid treatment guideline; Low cholesterol risk; low density lipoprotein cholesterol (LDL C); Randomized control trial (RCT); Statin; Total cholesterol (CH)

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TUMOR MARKER;

ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; HUMAN; MORTALITY; NEOPLASM; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84893625654     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: 10.4149/BLL_2014_013     Document Type: Article

References (58)

1. Schatzkin A, Hoover RN, Taylor PR et al. Serum cholesterol and cancer in the NHANES I epidemiologic followup study. National Health and Nutrition Examination Survey. Lancet 1987; 2: 298-301.
2. European Health for All Database, WHO Regional Offi ce for Europe, Copenhagen, updated January 2012, 59-65
3. Funaki NO, Tanaka J, Kohmoto M et al. Membrane fl uidity correlates with liver cancer cell proliferation and infi ltration potential. Oncol Rep 2001; 8 (3): 527-532.
4. Jacobs D, Blackburn H, Higgins M et al. Report of the Conference on low blood cholesterol: mortality associations. Circulation 1992; 86: 1046-1060.
5. Tschopp J, Masson D, Stanley KK. Structural / functional similarity between proteins involved in complement- and cytotoxic T-lymphocyte- mediated cytolysis. Nature 1986; 322: 831-834.
6. Muldoon MF, Marsland A, Flory JD et al. Immune system differences in men with hypo- or hypercholesterolemia. Clin Immunol Immunopathol 1997; 84: 145-149.
7. Míguez MJ, Rosenberg R, Burbano X et al. Cholesterol as a mediator of alcohol-induced risks for respiratory disease hospitalizations among people living with HIV. J AIDS Clin Res 2011; Special Issue 1.
8. Yasumasu T,Kazuo T, Sadayasu T et al. Effect of plasma lipoproteins on natural killer cell activity in the elderly population. J Gerontol 2003; 58A: 561-565.
9. Miersch S, Espey MG, Chaube R et al. Plasma membrane cholesterol content affects nitric oxide diffusion, dynamics and signaling. J Biol Chem 2008; 283 (27): 18513-18521.
10. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nature Reviews Cancer 2004; 4: 11-22.
11. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nature Reviews Immunology 2008; 8: 958-969.
12. International Collaborative Group: Circulating cholesterol level and risk of death from cancer in men aged 40-69 years: Experience of an international collaborative group. JAMA 1982; 248: 2853-2859.
13. Rose G, Shipley MJ. Plasma lipids and mortality: A source of error. Lancet 1980; 1: 523-526.
14. Sherwin R, Wentworth D, Cutler J et al. Serum cholesterol levels and cancer mortality in 361,662 men screened for the MRFIT. JAMA 1987; 257: 943-948.
15. Jacobs D, Blackburn H, Higgins M et al. Report of the Conference on low blood cholesterol: mortality associations. Circulation 1992; 86: 1046-1060.
16. Ravnskov U, McCully KS, Rosch PJ. The statin-low cholesterol- cancer conundrum. Q J Med 2012; 105: 383-388.
17. Williams RR, Sorlie PD, Feinleib M et al. Cancer incidence by levels of cholesterol. JAMA 1981; 245: 247-252.
18. Schatzkin A, Hoover RN, Taylor PR et al. Serum cholesterol and cancer in the NHANES I epidemiologic followup study. National Health and Nutrition Examination Survey. Lancet 1987; 2: 298-301.
19. Tornberg SA, Holm LE, Carstensen JM et al. Cancer incidence and cancer mortality in relation to serum cholesterol. J Natl Cancer Inst 1989; 81: 1917-1921.
20. Isles CG, Hole DJ, Gillis CR et al. Plasma cholesterol, coronary heart disease, and cancer in the Renfrew and Paisley survey. BMJ 1989; 298: 920-924.
21. Schuit AJ, Van Dijk CE, Dekker JM et al. Inverse association between serum total cholesterol and cancer mortality in Dutch civil servants. Am J Epidemiol 1993; 137 (9): 966-976.
22. Kreger BE, Anderson KM, Schatzkin A et al. Serum cholesterol level, body mass index, and the risk of colon cancer. The Framingham study. Cancer 1992; 70: 1038-1043.
23. Nago N, Ishikawa S, Goto T et al. Low cholesterol is associated with mortality from stroke, heart disease, and cancer: the Jichi Medical School Cohort Study. J Epidemiol 2011; 21 (1): 67-74.
24. Benn M, Tybjærg-Hansen A, Stender S et al. Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study. J Natl Cancer Inst 2011; 103 (6): 508-19.
25. Lavigne PM et al. Low LDL predates cancer risk by decades. Am J Coll Cardiol 2012; 19: 59-61.
26. Yang X, So WY, Ma RC et al. Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Care 2009; 32: 1826-1832.
27. DeMaria AN. Low-density lipoprotein reduction and cancer. J Amer Coll Cardiol 2007; 50: 421-422.
28. LaRosa JC. Means and ends of statins and low-density lipoprotein cholesterol lowering. J Amer Coll Cardiol 2007; 50: 419-420.
29. Yang X. Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. Canad Med Assoc J 2008; 179: 427-437.
30. Taylor ML, Wells BJ, Smolak MD. Statins and cancer: a meta-analysis of case- control studies. Wur J Cancer Prev 2008; 17: 259-268.
31. Rossebo AB, Pedersen TR, Boman K et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359: 1343.
32. Jafri H, Alsheikh-Ali AA, Karas RH. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid- altering therapy. J Am Coll Cardiol 2010; 55: 2846-33.
33. O'Riordan M. Statins not associated with cancer risk in large EMR database. Heart Wire 2011; July 21.
34. Menter DG, Ronnsauer VP, Harirforoosh S et al. Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites. PloS One 2011; 6: e 28813.
35. Bonovas S, Filioussi K, Tsavaris N et al. Statins and cancer risk: a literature- based meta- analysis and meta- regression analysis of 35 randomized controlled trials. J Clin Oncol 2006; 24: 4808-4817.
36. Bonovas S, Sitaras NM. Does pravastatin promote cancer in elderly patients? A meta- analysis. CMAJ 2007; 176: 649-654.
37. Sato S, Ajiki W, Kobayashi T et al. Pravastatin use and the fi ve year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study. J Epidemiol 2006; 16: 201-206.
38. Matsushita Y, Sugikara M, Kaburagi J et al. Pravastatin use and cancer risk: a meta- analysis of individual patient data from long-term prospective controlled trials in Japan. Pharmaco- epidemiol Drug Saf 2010; 19: 196-202.
39. Stein EA, Corsini A, Gompelowicz CR et al. Fluvastatin treatment is not associated with an increased incidence of cancer. Int J Clin Pract 2006; 60: 1028-1034.
40. Knoppala J, Lamiupaa A, Pukkala E. Statins and cancer: A systematic review and meta- analysis. Eur J Cancer 2008; 44: 2122-2132.
41. Heart Protection Study Group, Bulbulia R, Bowman L, Wallendszus K et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet 2011; 378: 2013-2020.
42. Alsheikh-Ali AA, Trikalinos TA, Kent MD et al. Statins, low density liporotein cholesterol, and risk of cancer. J Am Coll Cardiol 2008; 52: 1141.
43. Alsheikh-Ali AA, Karas RH. Ezetimibe, and the combination of ezetimibe/ simvastatin, and risk of cancer: A post- marketing analysis. J Clin Lipidol 2009; 2: 138-142.
44. Notarnicola M, Altomare DF, Correale M et al. Serum lipid profi le in colorectal cancer patients with and without synchronous distant metastases. Oncology 2005; 68: 371-374.
45. Bonovas S, Filioussi K, Flordeliis CS et al. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1,5 million patients. J clin Oncol 2007; 25: 3462-3468.
46. Jacobs EJ, Stevens VL, Newton CC et al. Plasma total, LDL and HDL cholesterol and risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control 2012; 23: 1289-1296.
47. Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: A meta- analysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 2008; 123: 899-904.
48. Liu YL, Ovian HX, Quin L et al. Association of serum lipid profi le with distant metastasis in breast cancer patients. In Chinese. Zhonghua Zhong Liu Za Zhi 2012; 34: 129-131.
49. Bonovas S, Filioussi K, Tsavaris N et al. Use of statins and breast cancer: a meta- analysis of seven randomized controlled trials and nine observational studies. J clin Oncol 2005; 23: 8606-8612.
50. Cui X, Xie Y, Chen M et al. Statin use and risk of pancreatic cancer: a meta-analysis. Cancer Causes Control 20'12; 7: 1099-1111.
51. Bonovas S, Filioussi K, Tsantes A et al. Use of statins and risk of haematological malignancies: a meta- anlysis of six randomized clinical trials and eight observational studies. Br J Clin Pharmacol 2007; 64: 255-262.
52. Freeman SR, Drake AL, Heilig LF et al. Statins, fi brates, and melanoma risk: a systematiuc review and meta-analysis. J Natl Cancer Inst 2006; 98: 1538-1546.
53. Harley CR, Gandhi SK, Heien H et al. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care. Expert Opin Pharmacother 2008; 9: 669-676.
54. Alsheikh-Ali AA, Madduburi PV, Han H et al. Effect of magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 2007; 50: 409.
55. Alsheikh-Ali AA, Lin JL, Abourjaily P et al. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease equivalents. Am J Cardiol 2006; 98: 1231-1233.
56. Mahdy Ali K, Wonnerk A, Huber K et al. Cardiovascular disease risk reduction by raising HDL cholesterol- current therapies and future opportunities. Br J Pharmacol 2012;10.1111/j. 1476-5381.
57. Evans M, Roberts A, Davies S et al. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Drugs 2004; 64: 1181-1196.
58. Stein EA, Mellis S, Yancopoulos GD et al. Effect of a Monoclonal Antibody to PCKS9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-1118.